Skip to main content
. 2008 Sep 15;112(6):2190–2198. doi: 10.1182/blood-2008-03-077966

Figure 3.

Figure 3

Model of leukemic transformation in MPD. Some patients develop JAK2V617F+ AML after JAK2V617F+ MPD, consistent with a JAK2V617F+ progenitor that undergoes leukemic transformation. However, some patients with JAK2V617F+ MPD transform to a JAK2V617F AML, consistent with a “pre-JAK2” clone, which is susceptible to leukemic transformation. Illustration by Debra Tyler.